This is a preview of subscription content, log in via an institution to check access.
Notes
The PLATelet inhibition and patient Outcomes (PLATO) trial received financial support from AstraZeneca.
Reference
Levin LA, et al. Health-Related Quality of Life of Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes-Results from the PLATO Trial. Value in Health 16: 574-580, No. 4, Jun 2013. Available from: URL: http://dx.doi.org/10.1016/j.jval.2013.01.013
Rights and permissions
About this article
Cite this article
Ticagrelor provides improved survival, similar QOL in ACS. PharmacoEcon Outcomes News 682, 10 (2013). https://doi.org/10.1007/s40274-013-0553-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0553-9